Answer
Aranesp (darbepoetin alfa) can be administered subcutaneously or intravenously to patients with chronic renal failure, with subcutaneous administration preferred in patients not receiving haemodialysis to avoid puncturing peripheral veins.
Sources for this answer
- Aranesp solution for injection in pre-filled syringe / Aranesp solution for injection in pre-filled syringe with needle guardAmgen Ltd · emc · SmPC §4.2 Posology and method of administration · Version 1Document updated
Sources checked